SCHEDULE: CVI Investments, Heights Capital Boost Processa Stake

CVI Investments and Heights Capital Management report a 9.0% beneficial ownership stake in Processa Pharmaceuticals, primarily through warrants.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") beneficially own 5,000,000 shares of Processa Pharmaceuticals, Inc. common stock.
• This ownership represents 9.0% of the company's outstanding common stock.
• The beneficially owned shares consist of shares issuable upon the exercise of warrants.
• The warrants are not exercisable to the extent that beneficial ownership would exceed 9.99%.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and exercises shared voting and dispositive power over these shares.
• Processa Pharmaceuticals, Inc. had 50,349,149 shares outstanding as of August 7, 2025, as reported in its Definitive Proxy Statement on Schedule 14A filed August 13, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual report of beneficial ownership, indicating institutional interest without providing performance or operational updates. It is neutral in sentiment.

Positives

• Increased institutional ownership by CVI Investments, Inc. and Heights Capital Management, Inc. may signal confidence in Processa Pharmaceuticals, Inc.'s future prospects.
• The investment through warrants indicates a long-term interest in the company's potential growth.

Negatives

• The 9.99% beneficial ownership cap on warrant exercise limits the immediate impact of this stake on the company's capital structure or control, potentially restricting the full conversion of warrants.

Risks

• The beneficial ownership of shares from warrants is capped at 9.99%, meaning the full potential of the warrants may not be realized if it pushes ownership above this threshold, which could affect the Reporting Persons' ability to fully convert their investment.

Future Outlook

No specific forward-looking statements or guidance from Processa Pharmaceuticals, Inc. are provided in this ownership filing. The filing only details the current beneficial ownership of the reporting entities.

Management Comments

• Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.
• Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

Institutional investors like CVI Investments and Heights Capital Management frequently take passive stakes in biotechnology and pharmaceutical companies, often through instruments like warrants, to gain exposure to potential growth without seeking control. This type of filing is common for funds managing diversified portfolios.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, indicating a passive investment stake below the 10% threshold that would typically trigger a Schedule 13D filing (which implies an intent to influence or control).
• The 9.99% beneficial ownership cap on warrant exercise is a common provision used by institutional investors to avoid triggering certain regulatory thresholds or poison pill provisions, aligning with standard practices for passive institutional investments.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a positive signal of investor confidence, potentially contributing to market stability.
• Management is unlikely to be directly impacted, as the filing explicitly states the investment is passive and not intended to influence control.

Key Dates

Recommendation

The filing indicates a significant institutional stake by CVI Investments and Heights Capital Management, representing 9.0% of Processa Pharmaceuticals. This suggests a degree of confidence from sophisticated investors. However, as a Schedule 13G, it explicitly states the investment is passive and not intended to influence control. Without additional information on the company's financial performance, pipeline progress, or strategic initiatives, this filing alone does not provide sufficient grounds for a strong buy or sell recommendation. It primarily serves as an update on the ownership structure, supporting a 'hold' stance for existing investors and a neutral view for potential new investors until more comprehensive data is available.

Keywords

Processa Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, pharmaceutical, biotech